put Our Experience to work for you

Expand the reach of your studies and find the right population using our global experience to help inform your portfolio and feasibility decisions.

we have a worldwide presence

Leverage our unique view of the world using our established resources in Africa, Asia, Europe, Latin America and North America.


Click on a highlighted country, state or pin to see details of our experience in that area, or to see our reach for a specific therapeutic area, select it from the dropdown menu.

How to use this map

Data current as of January 1, 2022. The boundaries and names on this map do not imply official endorsement or acceptance by FHI Clinical.

FHI Clinical Presence

FHI Clinical & FHI 360

FHI 360 Locations

We are localized

We know how to navigate location-specific challenges so you can be prepared for any circumstance regardless of study location.

FHI Clinical has the local resources and experience to keep your study moving forward:  engage with the local communities, work with still-developing regulatory agencies, ramp up quickly for an outbreak, implement contingency plans for natural disasters or political unrest and more.

We’re worldwide, but know how to navigate local challenges so you can be  prepared for any circumstance, regardless of study location.
We have local staff on the ground to help navigate location-specific challenges. From engaging with the local communities and working with still-developing regulatory agencies to ramping up quickly for an outbreak or implementing contingency plans for natural disasters or political unrest — FHI Clinical has the resources and experience to keep your study moving forward.

Successfully implementing studies in complex settings requires an understanding of and respect for the local communities.

Our far-reaching, in-country technical, regulatory and cultural knowledge has been developed over our long history of working globally.

Our experience helps us guide decisions about the best-fit countries and populations for your target indication.

africa

Geographic Coverage

We’ve been involved in observational studies, behavioral studies and clinical trials for epidemiology, spatial repellents, vaccines and treatments in 26 African countries.

Local Resources

FHI 360 or FHI Clinical offices and resources are located in 23 countries throughout Africa.

Priority Indications

Our research involvement has included COVID-19, Ebola, gastroenteritis, rotavirus gastroenteritis, malaria, malnutrition, meningitis, onchocerciasis, pneumonia, streptococcus pneumoniae, HIV, tuberculosis and HIV/tuberculosis co-infection.

we are globally connected

We are dedicated to developing and maintaining relationships with governments, regulatory agencies, other contract research organizations, sponsors, academic institutions, research sites and local communities. Importantly, we commit the needed resources to those relationships and become a trusted partner.

Access the skill sets necessary to quickly and efficiently combat disease.

Sustainable relationships with key partners ensure proactive disease management as well as rapid responses to immediate needs.

Play Video

Reducing the global disease burden is only possible when we pool our resources and skills. We have collaborative partnerships with:

Through these relationships as well as those we’ve established in communities around the world, we have access to a global network of:
We also act as the coordinating and operations center for clinical research networks in Africa, Asia, Latin America and the United States.

Participation in research networks

Access research-ready sites through established networks in resource-limited areas. As a trusted network partner, we contribute our expertise to building sustainable research capacity that aligns with the local health and research priorities.

WE SUPPORT MANY THERAPEUTIC AREAS

Leverage our expertise to address challenges across many therapeutic areas in both adult and pediatric populations:

SPECIFIC INFECTIOUS DISEASE EXPERTISE

Our team is particularly passionate about addressing infectious diseases, neglected tropical diseases and emerging and reemerging diseases in vulnerable populations:

Learn more about our specific experience through our case studies:

Case Study
Phase II Trial of a Chikungunya Vaccine in the Caribbean

Phase II Trial of a Chikungunya Vaccine in the Caribbean

The study team maintained a 91% retention rate in a study of a Chikungunya virus (CHIKV) vaccine, despite study disruptions due to natural disasters, including Hurricane Maria, and political unrest near the sites in five Caribbean countries in a CHIKV endemic region.
Case Study
Site Monitoring & Management in a Clinical Trial of a Spatial Repellent for Vector-Borne Disease Control

Site Monitoring & Management in a Clinical Trial of a Spatial Repellent for Vector-Borne Disease Control

The FHI Clinical project team supported site monitoring, site management and project management to assist the University of Notre Dame investigators achieve a level of rigor not typically required for a non-medical product in their double-blinded, randomized-cluster, placebo-controlled clinical trial of a spatial repellent against mosquitoes for malaria prevention.
Case Study
Rapid Site Assessment and Recommendations for Clinical Trials of a New Malaria Treatment

Rapid Site Assessment and Recommendations for Clinical Trials of a New Malaria Treatment

Targeted geographic areas for the development of an antimalarial drug by Novartis included malaria-endemic regions in Africa and Asia, and Novartis requested assistance identifying and assessing potential clinical sites for their planned clinical trial. Our team conducted 38 rapid, in-depth, 2.5-day site feasibility assessments in the 18 countries.
Case Study
Providing Site Monitoring and Management Expertise in Malaria Vaccine Trials in Equatorial Guinea

Providing Site Monitoring and Management Expertise in Malaria Vaccine Trials in Equatorial Guinea

Data monitoring strategies implemented by our bilingual CRA helped eliminate the backlog to ensure timely database lock in a phase 2 trial for Sanaria's innovative PfSPZ Vaccine for malaria in Equatorial Guinea, an area with limited prior research experience.
Case Study
Phase II/IIb Trial of a Zika Vaccine Spanning Nine Countries

Phase II/IIb Trial of a Zika Vaccine Spanning Nine Countries

In a study conducted at 17 sites spanning nine countries in a Zika endemic region of the Americas and Caribbean, timely staffing of contract research associates (CRAs) was enabled by the project team’s network of bilingual resources and knowledge of local hiring practices.
Case Study
Clinical Research Training to Support Capacity Building in Liberia

Clinical Research Training to Support Capacity Building in Liberia

To equip Liberia with the ability to respond to ongoing health issues and potential outbreaks, a US government contract provided funding to train local leaders in Liberia’s clinical research infrastructure network. The training aimed to build a solid foundation to conduct international quality clinical research.
Case Study
Building Capacity for Tuberculosis Research in China: The China TB Clinical Trials Consortium (CTCTC)

Building Capacity for Tuberculosis Research in China: The China TB Clinical Trials Consortium (CTCTC)

To help address the high global TB incidence and related death rate, the China TB Clinical Trials Consortium (CTCTC) was established by government and industry partners to help build clinical research capacity in China, which has a particularly high tuberculosis incidence.
Case Study
Rapid Study Start-Up for the Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE)

Rapid Study Start-Up for the Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE)

Within a challenging, resource-limited setting, the project team succeeded in reaching FP/FV six weeks after arrival in Sierra Leone and 99.998% accuracy of the planned-to-execute budget.
Case Study
Rescue of an Ongoing Global, Multi-Site Oncology Trial

Rescue of an Ongoing Global, Multi-Site Oncology Trial

In a Phase 3 study with a lengthy intervention for colorectal cancer, the project team reached a 70% retention rate, with steadily increasing enrollment rates, by implementing strategies to address poor patient enrollment and retention.